818 F. Supp. 2d 1177
C.D. Cal.2011Background
- Gina Delarosa sues Boiron, Inc. in California federal court for misleading marketing of Children's Coldcalm.
- Coldcalm is a homeopathic OTC drug, advertised to relieve cold symptoms on packaging and a website.
- Plaintiff purchased Coldcalm and did not receive the advertised relief; suit seeks CLRA, fraud, and UCL relief on behalf of California purchasers.
- Defendant removals raised federal preemption challenges under the FDCA and its regulations.
- Court explains FDCA framework: non-homeopathic OTC drugs are regulated via monographs; homeopathic drugs are treated differently and not fully FDA-evaluated.
- Court denies Boiron’s motion for judgment on the pleadings, allowing the claims to proceed.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Is there express preemption under FDCA § 379r for homeopathic OTC drugs? | Delarosa argues § 379r(a) preempts state claims. | Boiron argues homeopathic drugs fall within § 379r(a) and are preempted, with § 379r(d) limited. | Exercise of § 379r(d) narrows preemption to homeopathic drugs. |
| Are Delarosa’s claims preempted because they allege misbranding under FDCA? | Claims mirror FDCA labeling provisions and seek similar relief. | Claims require changes beyond FDA-approved labeling; thus preempted. | Claims not preempted where FDCA labeling would not be altered; but misbranding claims may be preempted if they seek different requirements. |
| Are Delarosa’s claims preempted under implied preemption theories? | State-law claims complement FDA framework. | Conflicts with federal goals; field/conflict preemption applies. | Implied preemption rejected; no field or conflict preemption established. |
| Do the CLRA and UCL claims survive under pleading standards and notice requirements? | Fraud and CLRA allegations are sufficiently pleaded; CLRA notice provided. | Plaintiff fails to meet heightened fraud pleading and CLRA notice specifics. | Plaintiff adequately pleads fraud; CLRA notice satisfied for purposes of 12(c) motion. |
Key Cases Cited
- Wyeth v. Levine, 555 U.S. 555 (Supreme Court 2009) (federal preemption framework for FDA regulation of drugs)
- Riegel v. Medtronic, 552 U.S. 312 (Supreme Court 2008) (state strict liability claims preempted by FDCA in certain contexts)
- Cipollone v. Liggett Group, 505 U.S. 504 (Supreme Court 1992) (Supremacy Clause and preemption principles)
- Carter v. Novartis Consumer Health, Inc., 582 F. Supp. 2d 1271 (C.D. Cal. 2008) (preemption framework for nonprescription drugs; FDCA monograph effects)